A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 3.305 USD -4.76% Market Closed
Market Cap: $403.2m

Operating Margin

-129.5%
Current
Declining
by 64.2%
vs 3-y average of -65.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-129.5%
=
Operating Income
$-56.2m
/
Revenue
$43.4m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-129.5%
=
Operating Income
$-56.2m
/
Revenue
$43.4m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Aquestive Therapeutics Inc
NASDAQ:AQST
406.3m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
954.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
546.2B USD
Loading...
CH
Roche Holding AG
SIX:ROG
268.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
265.4B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.6B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.4B EUR
Loading...

Market Distribution

Lower than 86% of companies in the United States of America
Percentile
14th
Based on 14 112 companies
14th percentile
-129.5%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Aquestive Therapeutics Inc
Glance View

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 157 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered products to deliver molecules, providing alternatives to care therapies. The company is engaged in advancing a late-stage product pipeline focused on treating diseases of the central nervous system (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. The firm's CNS portfolio, which is focused on epilepsy includes Sympazan and Libervant. The active programs in its complex molecule pipeline portfolio are: AQST-109-SF, AQST-108-SF, and AQST-108-SF. Its PharmFilm technology develops medicines that offer non-invasive delivery, customized suitability for patients with dysphagia, or trouble swallowing, can be administered without water and ensures consistent therapeutic dosing. PharmFilm is comprised of polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs) and excipients in place.

AQST Intrinsic Value
1.673 USD
Overvaluation 49%
Intrinsic Value
Price
A
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-129.5%
=
Operating Income
$-56.2m
/
Revenue
$43.4m
What is Aquestive Therapeutics Inc's current Operating Margin?

The current Operating Margin for Aquestive Therapeutics Inc is -129.5%, which is below its 3-year median of -65.3%.

How has Operating Margin changed over time?

Over the last 3 years, Aquestive Therapeutics Inc’s Operating Margin has decreased from -118.2% to -129.5%. During this period, it reached a low of -129.5% on Sep 30, 2025 and a high of -26% on Jun 30, 2024.

Back to Top